Table 2.
Genetic influences of HtrA1 polymorphisms on treatment response among stage III colon cancer cases receiving 5-FU-based chemotherapy.
| SNPs | Chemotherapy efficacy | Rough results | Adjusted results | ||||
|---|---|---|---|---|---|---|---|
| CR+PR (n, %) | SD+PD (n, %) | Response rate (%) | OR (95% CI) | P | OR (95% CI) | P | |
| rs1049331 | |||||||
| CC | 19 (33.93%) | 11 (22.45%) | 63.33% | Reference | – | Reference | – |
| CT | 32 (64.29%) | 26 (53.06%) | 55.17% | 1.403 (0.568–3.469) | 0.462 | 1.247 (0.508–3.061) | 0.629 |
| TT | 5 (8.93%) | 12 (24.49%) | 29.41% | 4.145 (1.152–14.918) | 0.025 | 3.758 (1.265–11.343) | 0.021 |
| C | 70 (62.50%) | 48 (48.98%) | 59.32% | Reference | – | Reference | – |
| T | 42 (37.50%) | 50 (51.02%) | 45.65% | 1.736 (1.001–3.011) | 0.049 | 1.801 (1.054–2.932) | 0.039 |
| rs11200638 | |||||||
| GG | 18 (32.14%) | 11 (22.45%) | 62.07% | Reference | – | Reference | – |
| GA | 30 (53.57%) | 29 (59.18%) | 50.85% | 1.528 (0.638–3.919) | 0.320 | 1.609 (0.700–4.154) | 0.296 |
| AA | 8 (14.29%) | 9 (18.37%) | 47.06% | 1.841 (0.548–6.188) | 0.322 | 1.912 (0.602–7.001) | 0.317 |
| G | 66 (58.93%) | 51 (52.04%) | 56.41% | Reference | – | Reference | – |
| A | 46 (41.07%) | 47 (47.96%) | 49.46% | 1.322 (0.765–2.284) | 0.316 | 1.451 (0.802–2.147) | 0.285 |